2013
DOI: 10.1097/inf.0b013e31828e9b99
|View full text |Cite
|
Sign up to set email alerts
|

Implementation of Occult Hepatitis Screening in the Spanish Cohort of HIV-infected Pediatric Patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2014
2014
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(4 citation statements)
references
References 90 publications
0
4
0
Order By: Relevance
“…Furthermore, the available data suggest seronegative patients have a different clinical evolution and should therefore be evaluated separately. Another factor that is common in HIV patients and that is known to affect [46] Iran 3 (13.6) 2 (9.1) ND 1 (4.5) Bagaglio et al [47] Italy 9 (31.0) 9 (31.0) ND ND Bell et al [48] Africa [51] Spain 6 (2.4) 2 (0.8) 4 (1.6) ND Filippini et al [13] Italy 17 (20.0) 11 (12.8) 3 (3.5) 3 (3.5) Firnhaber et al [23] Africa 38 (88.4) 38 (88.4) ND ND Gupta et al [30] India 24 (45.3) 13 (24.5) 11 (20.8) ND Hakeem et al [52] Scotland 2 (2.8) 2( 2.9) ND ND Jardim et al [19] Brazil 8 (5.0) 2 (1.3) 6 (3.8) ND Khamduang et al [35] Thailand 47 (23.5) 47 (23.5) ND ND Liang et al [53] Taiwan 3 (2.3) 3 (2.3) ND ND Lo Re et al [54] United States 17 (10.0) 10 (5.6) 7 (3.9) ND Loustaud-Ratti et al [55] France [24] Africa 51 (10.0) 51 (11.8) ND ND Neau et al [58] France 1 (0.6) 1 (0.6) ND ND Nebbia et al [59] England 48 (14.0) 48 (14.0) ND ND Opaleye et al [25] Nigeria 21 (11.2) 8 (4.3) 9 (4.8) 2 (1.1) Panigrahi et al [26] India 12 (10.7) 9 (8.0) 3 (2.7) ND Santos et al [20] Brazil 16 (15.8) 2 4 (4.0) 12 (11.9) ND Sen et al [27] India 1 (5.6) 2 1 (5.6) ND ND Shire et al [60] United States 4 (10.5) 4 (10.5) ND ND Shire et al [61] United States 12 (30.2) 3 (7.0) 5 1 (11.6) 5 (11.6) Sucupira et al [21] Brazil 6 (18.8) 2 3 (9.4) 3 (9.4) ND Torres Barranda et al [22] Mexico 7 (18.4) 1 (2.6) 1 (2.6) 5 (13.2) Tramuto et al [62] Italy 24 (5.9) 8 (2.0) 7 1 (1.7) 9 (2.2) Tsui et al [63] United States 8 (2.0) 8 (2.0) ND ND 1 In some studies the anti-HBsAg positive group was also included; 2 Prevalence calculated using the reported data; anti-HBsAg+, antibodies against hepatitis B surface antigen positive; anti-HBcAg+ antibodies against hepatitis B core antigen positive. Prevalence (%) were included for each group of patients studied according the HBV serological markers (Anti-HBsAg-/anti-HBcAg+, Anti-HBsAg+/anti-HBcAg+, Anti-HBsAg-/anti-HBcAg-).…”
Section: Clinical Significancementioning
confidence: 99%
“…Furthermore, the available data suggest seronegative patients have a different clinical evolution and should therefore be evaluated separately. Another factor that is common in HIV patients and that is known to affect [46] Iran 3 (13.6) 2 (9.1) ND 1 (4.5) Bagaglio et al [47] Italy 9 (31.0) 9 (31.0) ND ND Bell et al [48] Africa [51] Spain 6 (2.4) 2 (0.8) 4 (1.6) ND Filippini et al [13] Italy 17 (20.0) 11 (12.8) 3 (3.5) 3 (3.5) Firnhaber et al [23] Africa 38 (88.4) 38 (88.4) ND ND Gupta et al [30] India 24 (45.3) 13 (24.5) 11 (20.8) ND Hakeem et al [52] Scotland 2 (2.8) 2( 2.9) ND ND Jardim et al [19] Brazil 8 (5.0) 2 (1.3) 6 (3.8) ND Khamduang et al [35] Thailand 47 (23.5) 47 (23.5) ND ND Liang et al [53] Taiwan 3 (2.3) 3 (2.3) ND ND Lo Re et al [54] United States 17 (10.0) 10 (5.6) 7 (3.9) ND Loustaud-Ratti et al [55] France [24] Africa 51 (10.0) 51 (11.8) ND ND Neau et al [58] France 1 (0.6) 1 (0.6) ND ND Nebbia et al [59] England 48 (14.0) 48 (14.0) ND ND Opaleye et al [25] Nigeria 21 (11.2) 8 (4.3) 9 (4.8) 2 (1.1) Panigrahi et al [26] India 12 (10.7) 9 (8.0) 3 (2.7) ND Santos et al [20] Brazil 16 (15.8) 2 4 (4.0) 12 (11.9) ND Sen et al [27] India 1 (5.6) 2 1 (5.6) ND ND Shire et al [60] United States 4 (10.5) 4 (10.5) ND ND Shire et al [61] United States 12 (30.2) 3 (7.0) 5 1 (11.6) 5 (11.6) Sucupira et al [21] Brazil 6 (18.8) 2 3 (9.4) 3 (9.4) ND Torres Barranda et al [22] Mexico 7 (18.4) 1 (2.6) 1 (2.6) 5 (13.2) Tramuto et al [62] Italy 24 (5.9) 8 (2.0) 7 1 (1.7) 9 (2.2) Tsui et al [63] United States 8 (2.0) 8 (2.0) ND ND 1 In some studies the anti-HBsAg positive group was also included; 2 Prevalence calculated using the reported data; anti-HBsAg+, antibodies against hepatitis B surface antigen positive; anti-HBcAg+ antibodies against hepatitis B core antigen positive. Prevalence (%) were included for each group of patients studied according the HBV serological markers (Anti-HBsAg-/anti-HBcAg+, Anti-HBsAg+/anti-HBcAg+, Anti-HBsAg-/anti-HBcAg-).…”
Section: Clinical Significancementioning
confidence: 99%
“…An interesting observation was recently reported in the study by Dapena et al (38) in which of 17 children co-infected, 2 (12%) were HCV RNA positive but anti-HCV negative, suggesting that antibodies assays for HCV in the context of co-infection could miss some cases of seronegative hepatitis C.…”
Section: Viremia and Alanine Aminotransferase Levels In Co-infected Cmentioning
confidence: 82%
“…In the Spanish prospective study, the rate of spontaneous clearance was 17.5% in monoinfected children while no co-infected child spontaneously cleared the virus (32). Overall, only 12 children across the different HCV/HIV reported pediatric cohorts presented spontaneous clearance of HCV and no data were provided on its timing (3,27,(32)(33)(34)38).…”
Section: Spontaneous Clearance Of Hcv In Co-infected Childrenmentioning
confidence: 99%
“…Studies in adults with chronic liver disease (CLD) have shown a variable prevalence of OBI ranging from 2 to 32% depending on the prevalence of HBV infection in the particular general population and the sensitivity of the assay used for detection of HBV DNA [4,5]. However, studies on OBI in children are limited largely to those with hematological disorders and HIV infection [6,7].The current study aimed to prospectively evaluate the prevalence of OBI in children with CLD.…”
Section: Introductionmentioning
confidence: 96%